A Prospective Comparative Study of Autologous Bone Marrow-Derived and Adipose Tissue-Derived Mesenchymal Stem Cells Versus Platelet-Rich Plasma and Standard Therapy in Patients With Organic Erectile Dysfunction
Key facts
- Who runs it
- National Scientific Medical Center, Kazakhstan
- Where
- Kazakhstan1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 2
- People taking part
- 100 people enrolled
- Started
- 9 Sept 2024
- Ended
- 1 Nov 2026
- Type of study
- Interventional, 5 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Autologous Bone marrow-derived Mesenchymal Stem Cells (BMSC)
- Autologous Platelet-Rich Plasma (4 mL)
- Autologous Platelet-Rich Plasma (6 mL)
- Adipose Tissue Mesenchymal Stromal Cells (ADSC)
- Low-intensity radial shock wave therapy (Li-SWT)
- Record updated
- 22 April 2026
Who can take part
- Age
- 18 years to 70 years
- Sex
- Men only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Male sex, aged between 18 and 70 years
- Confirmed diagnosis of organic erectile dysfunction (e.g., vasculogenic, diabetic, or post-traumatic) for a duration of at least 6 months
- Documented resistance or inadequate response to first-line therapies, such as Phosphodiesterase type 5 inhibitors (PDE5i)
- IIEF-5 (International Index of Erectile Function) score < 21 at baseline
- Stable relationship with a partner for the duration of the study
- Ability to understand the study procedures and provide written informed consent
Who cannot take part
- Testosterone deficiency (Hypogonadism) that has not been stabilized by hormone replacement therapy
- Anatomical deformities of the penis (e.g., Peyronie's disease, severe penile curvature, or fibrosis that prevents injection)
- History of pelvic malignancy (e.g., prostate or bladder cancer) or undergoing active radiation/chemotherapy
- Active infection (local or systemic) or skin diseases at the site of the intended injection
- Hematological disorders, such as severe anemia, coagulopathy, thrombocytopenia, or current use of anticoagulants that cannot be safely paused
- History of drug or alcohol abuse that may interfere with study compliance
- Uncontrolled systemic diseases, including decompensated diabetes mellitus (HbA1c > 9%), severe cardiovascular disease, or uncontrolled hypertension
- Psychogenic erectile dysfunction (not related to organic causes)
- Participation in another clinical trial involving experimental treatments for erectile dysfunction within the last 3 months
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Erectile dysfunction (ED) is a common condition characterized by the inability to achieve or maintain an erection sufficient for satisfactory sexual activity. It can significantly affect physical health, emotional well-being, and quality of life for both patients and their partners. Standard treatment options include medications such as phosphodiesterase type 5 inhibitors, vacuum devices, intracavernosal or transurethral therapies, and surgical implantation of penile prostheses. In recent years, low-intensity shock wave therapy has also been introduced as a treatment option. However, these approaches may have limitations in effectiveness, invasiveness, or long-term outcomes, highlighting the need for alternative therapies.
Read full original descriptionShow less
Advances in regenerative medicine have introduced new potential treatment strategies, including the use of autologous mesenchymal stem cells derived from bone marrow or adipose tissue. These therapies aim to improve tissue repair and restore erectile function. Previous preclinical and clinical studies suggest that mesenchymal stem cell therapy may be safe and effective, but direct comparisons between different sources of stem cells remain limited.
This prospective study aims to evaluate and compare the safety and effectiveness of autologous bone marrow-derived mesenchymal stem cells, adipose tissue-derived mesenchymal stromal cells, and platelet-rich plasma (PRP) therapy in patients with organic erectile dysfunction. A control group receiving standard conservative treatment, including low-intensity shock wave therapy, will also be included.
The study will be conducted in a population of patients in Kazakhstan and will assess outcomes before and after treatment to determine improvements in erectile function and overall patient well-being. The results may help identify more effective and regenerative treatment approaches for patients with organic erectile dysfunction.
The 5 groups in the trial
- Autologous Bone Marrow Mesenchymal Stem Cells (BMSC)Treatment being tested
Patients receive a single intracavernosal injection of autologous bone marrow mesenchymal stem cells at a concentration of approximately 1.7 × 10⁸ cells. The intervention involves the auto-collection of 27 ml of bone marrow, which is processed and separated into a 4 ml volume for introduction into the tissue of the cavernous bodies.
Treatment: Autologous Bone marrow-derived Mesenchymal Stem Cells (BMSC)
- Autologous Adipose Tissue Mesenchymal Stromal Cells (ADSC)Treatment being tested
Patients receive a single intracavernosal injection of at least 25 x 10⁶ autologous adipose tissue-derived stromal cells. These cells are obtained via lipoaspiration of 50 ml of water-fat suspension material and processed into a total volume of 4 ml for injection.
Treatment: Adipose Tissue Mesenchymal Stromal Cells (ADSC)
- Standard Care plus Shock Wave Therapy (SWT)Existing treatment, for comparison
Patients receive standard conservative treatment according to Ministry of Health clinical protocols, supplemented by a course of low-intensity radial shock wave therapy (SWT). The course includes 6 total sessions (2 sessions per week), with 2500 shocks delivered to 5 zones of the corpora cavernosa per session .
Treatment: Low-intensity radial shock wave therapy (Li-SWT)
- Autologous Platelet-Rich Plasma (PRP) 4 mLTreatment being tested
Patients receive three intracavernosal injection sessions of 4 mL of autologous platelet-rich plasma (PRP) at 3-week intervals. The PRP is prepared from 22 mL of venous blood with 1.2 mL of citrate-phosphate-dextrose (CPD) added, centrifuged to achieve a platelet concentration of ≥ 1 million/µL (total platelet count of 4000 × 10⁶).
Treatment: Autologous Platelet-Rich Plasma (4 mL)
- Autologous Platelet-Rich Plasma (PRP) 6 mLTreatment being tested
Patients receive three intracavernosal injection sessions of 6 mL of autologous platelet-rich plasma (PRP) at 3-week intervals. The PRP is prepared from 33 mL of venous blood with 1.8 mL of citrate-phosphate-dextrose (CPD) added, centrifuged to achieve a platelet concentration of ≥ 1 million/µL (total platelet count of 6000 × 10⁶).
Treatment: Autologous Platelet-Rich Plasma (6 mL)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 22 April 2026